Mengxing Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mengxing Wang has a total of 222 co-authors. Here are the top co-authors by number of shared publications:
- Yuesong Pan
Capital Medical University
19 shared publications - Yongjun Wang
Department of Neurology, Beijing Tiantan Hospital affiliated to Capital Medical University, Beijing, China
14 shared publications - Jing Jing
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
10 shared publications - Yilong Wang
Capital Medical University
10 shared publications Xia Meng
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
8 shared publications- Xiaochuan Huo
Department of Cerebral Vascular Disease, Neurological Disease Center, Beijing Anzhen Hospital, Capital Medical University, China (X.Z., X.T., S.L., X.H.).
7 shared publications
Latest Publications
- Open Access
- 7 July 2026
- Published by BMJ in Stroke and Vascular Neurology
Association between ASPECTS regions and clinical outcomes following endovascular therapy in patients with large infarcts: a post hoc analysis of the ANGEL-ASPECT trial
Objective: To explore whether clinical outcomes following endovascular therapy (EVT) may differ according to infarct regions assessed by the Alberta Stroke Program Early CT Score (ASPECTS) in patients with large infarcts. Methods: This post hoc analysis of the ANGEL-ASPECT study included patients with acute ischaemic stroke due to anterior circulation large vessel occlusion and large infarcts. Patients were randomised to EVT or standard medical therapy (SMT) and stratified based on ASPECTS into two groups: subcortical regions involvement (caudate, lenticular nucleus or internal capsule) and cortical regions involvement (cortical areas). The primary outcome was the 90-day modified Rankin Scale (mRS) score. ANGEL-ASPECT is signed up to ClinicalTrials.gov, NCT04551664 . Results: Of 455 patients, 395 (86.81%) with subcortical regions and 60 (13.19%) cortical regions infarcts. EVT was associated with a favourable shift in 90-day mRS scores in the subcortical regions group (OR 1.65; 95% CI 1.16 to 2.34; p<0.001), whereas no statistically significant difference was observed in the cortical regions group (OR 1.47; 95% CI 0.59 to 3.66; p=0.09). In the subcortical regions group, EVT was associated with better outcomes in left-side infarcts (OR 1.73; 95% CI 1.04 to 2.89; p=0.04). Similar trends were not statistically significant in right-side infarcts (OR 1.57; 95% CI 0.97 to 2.53; p=0.07). Conclusions: In this exploratory post hoc analysis, EVT was associated with more favourable functional outcomes in patients with subcortical region involvement, particularly in left-sided infarcts. However, no significant interaction between infarct location and treatment assignment was observed, and these findings should be considered hypothesis-generating.
- 7 July 2026
- Published by BMJ in Stroke and Vascular Neurology
Open AccessAssociation between ASPECTS regions and clinical outcomes following endovascular therapy in patients with large infarcts: a post hoc analysis of the ANGEL-ASPECT trial
Objective: To explore whether clinical outcomes following endovascular therapy (EVT) may differ according to infarct regions assessed by the Alberta Stroke Program Early CT Score (ASPECTS) in patients with large infarcts. Methods: This post hoc analysis of the ANGEL-ASPECT study included patients with acute ischaemic stroke due to anterior circulation large vessel occlusion and large infarcts. Patients were randomised to EVT or standard medical therapy (SMT) and stratified based on ASPECTS into two groups: subcortical regions involvement (caudate, lenticular nucleus or internal capsule) and cortical regions involvement (cortical areas). The primary outcome was the 90-day modified Rankin Scale (mRS) score. ANGEL-ASPECT is signed up to ClinicalTrials.gov, NCT04551664 . Results: Of 455 patients, 395 (86.81%) with subcortical regions and 60 (13.19%) cortical regions infarcts. EVT was associated with a favourable shift in 90-day mRS scores in the subcortical regions group (OR 1.65; 95% CI 1.16 to 2.34; p<0.001), whereas no statistically significant difference was observed in the cortical regions group (OR 1.47; 95% CI 0.59 to 3.66; p=0.09). In the subcortical regions group, EVT was associated with better outcomes in left-side infarcts (OR 1.73; 95% CI 1.04 to 2.89; p=0.04). Similar trends were not statistically significant in right-side infarcts (OR 1.57; 95% CI 0.97 to 2.53; p=0.07). Conclusions: In this exploratory post hoc analysis, EVT was associated with more favourable functional outcomes in patients with subcortical region involvement, particularly in left-sided infarcts. However, no significant interaction between infarct location and treatment assignment was observed, and these findings should be considered hypothesis-generating.
- Open Access
- 26 June 2026
- Published by BMJ in Stroke and Vascular Neurology
Predictors of functional outcomes after endovascular therapy in acute large infarct: an ANGEL-ASPECT subanalysis
Background and purpose: Recent randomised clinical trials have shown that endovascular treatment (EVT) for patients with acute ischaemic stroke (AIS) and a large infarct core is safe and effective. This study sought to identify which factors predict favourable outcomes in AIS patients with a large infarct core who received EVT in the ANGEL-ASPECT trial. Methods: Patients from the ANGEL-ASPECT trial receiving EVT were enrolled in this analysis. They were categorised based on 90-day outcomes: good functional outcome (modified Rankin Scale (mRS) score 0–2) and independent ambulation (mRS score 0–3). A comparison of baseline and procedural characteristics was performed across the groups and logistic regression was performed to identify predictors of favourable outcomes. Results: Of 230 AIS participants with large infarct core undergoing EVT, independent predictors differed between outcome levels. For functional independence (mRS 0–2), predictors were male sex, lower systolic blood pressure (SBP) and National Institutes of Health Stroke Scale (NIHSS) score, smaller infarct volume, fewer thrombectomy attempts, and notably, the presence of early neurological improvement (ENI) at 36 hours (OR 19.62, 95% CI 2.28 to 168.52). For independent ambulation (mRS 0–3), predictors were younger age, lower SBP and NIHSS score, successful reperfusion, lower platelet-to-lymphocyte ratio and absence of decompressive hemicraniectomy (OR 20.00, 95% CI 2.04 to 196.08). Conclusions: This analysis delineates distinct predictors for different levels of recovery after EVT in large-core stroke. Beyond confirming the prognostic value of established factors (such as age, NIHSS and reperfusion), it highlights the novel high-impact prognostic factors for large-core AIS patients post-EVT: ENI for functional independence. Furthermore, the need for decompressive hemicraniectomy, a marker of severe cerebral oedema, was strongly linked to a lower probability of achieving independent ambulation. These findings may aid in early prognostication and refined patient management for this high-risk population. Trial registration number: NCT04551664 .
- 26 June 2026
- Published by BMJ in Stroke and Vascular Neurology
Open AccessPredictors of functional outcomes after endovascular therapy in acute large infarct: an ANGEL-ASPECT subanalysis
Background and purpose: Recent randomised clinical trials have shown that endovascular treatment (EVT) for patients with acute ischaemic stroke (AIS) and a large infarct core is safe and effective. This study sought to identify which factors predict favourable outcomes in AIS patients with a large infarct core who received EVT in the ANGEL-ASPECT trial. Methods: Patients from the ANGEL-ASPECT trial receiving EVT were enrolled in this analysis. They were categorised based on 90-day outcomes: good functional outcome (modified Rankin Scale (mRS) score 0–2) and independent ambulation (mRS score 0–3). A comparison of baseline and procedural characteristics was performed across the groups and logistic regression was performed to identify predictors of favourable outcomes. Results: Of 230 AIS participants with large infarct core undergoing EVT, independent predictors differed between outcome levels. For functional independence (mRS 0–2), predictors were male sex, lower systolic blood pressure (SBP) and National Institutes of Health Stroke Scale (NIHSS) score, smaller infarct volume, fewer thrombectomy attempts, and notably, the presence of early neurological improvement (ENI) at 36 hours (OR 19.62, 95% CI 2.28 to 168.52). For independent ambulation (mRS 0–3), predictors were younger age, lower SBP and NIHSS score, successful reperfusion, lower platelet-to-lymphocyte ratio and absence of decompressive hemicraniectomy (OR 20.00, 95% CI 2.04 to 196.08). Conclusions: This analysis delineates distinct predictors for different levels of recovery after EVT in large-core stroke. Beyond confirming the prognostic value of established factors (such as age, NIHSS and reperfusion), it highlights the novel high-impact prognostic factors for large-core AIS patients post-EVT: ENI for functional independence. Furthermore, the need for decompressive hemicraniectomy, a marker of severe cerebral oedema, was strongly linked to a lower probability of achieving independent ambulation. These findings may aid in early prognostication and refined patient management for this high-risk population. Trial registration number: NCT04551664 .
- Open Access
- 27 May 2026
- Published by BMJ in Stroke and Vascular Neurology
Renal function and effect of early antihypertensive therapy in acute ischaemic stroke: a subgroup analysis of the CATIS-2 trial
Background: The role of renal function in patients with acute ischaemic stroke (AIS) receiving blood pressure (BP) lowering therapy remains incompletely understood. In this prespecified subgroup analysis of the CATIS-2 trial, we tested the hypothesis that baseline estimated glomerular filtration rate (eGFR) affects the relationship between early antihypertensive therapy and outcomes in AIS. Methods: In the CATIS-2 trial, AIS patients were randomly assigned to early treatment (initiating BP-lowering agents within 24–48 hours of stroke onset) or delayed treatment (withholding such agents until day 8). The composite of functional dependence or death (modified Rankin Scale score ≥3) at day 90 was defined as the primary outcome. The treatment effect was analysed between different baseline eGFR values (<90 versus ≥90 mL/min per 1.73 m²). Results: 4685 patients were finally enrolled. Among 1061 patients with eGFR<90, the risk of the primary outcome was higher in early treatment compared with delayed treatment (15.3% vs 10.5%; OR (OR) 1.55, 95% CI 1.07–2.23; p=0.02). In 3624 patients with eGFR≥90, no such difference was observed (10.7% vs 10.2%; OR 1.05, 95% CI 0.85 to 1.30; p=0.63). The interaction was marginally significant (p=0.07). Conclusions: The modification effect of renal function on different antihypertensive timing for AIS was not observed. Further, adequately powered studies were warranted. Trial registration number: NCT03479554 .
- 27 May 2026
- Published by BMJ in Stroke and Vascular Neurology
Open AccessRenal function and effect of early antihypertensive therapy in acute ischaemic stroke: a subgroup analysis of the CATIS-2 trial
Background: The role of renal function in patients with acute ischaemic stroke (AIS) receiving blood pressure (BP) lowering therapy remains incompletely understood. In this prespecified subgroup analysis of the CATIS-2 trial, we tested the hypothesis that baseline estimated glomerular filtration rate (eGFR) affects the relationship between early antihypertensive therapy and outcomes in AIS. Methods: In the CATIS-2 trial, AIS patients were randomly assigned to early treatment (initiating BP-lowering agents within 24–48 hours of stroke onset) or delayed treatment (withholding such agents until day 8). The composite of functional dependence or death (modified Rankin Scale score ≥3) at day 90 was defined as the primary outcome. The treatment effect was analysed between different baseline eGFR values (<90 versus ≥90 mL/min per 1.73 m²). Results: 4685 patients were finally enrolled. Among 1061 patients with eGFR<90, the risk of the primary outcome was higher in early treatment compared with delayed treatment (15.3% vs 10.5%; OR (OR) 1.55, 95% CI 1.07–2.23; p=0.02). In 3624 patients with eGFR≥90, no such difference was observed (10.7% vs 10.2%; OR 1.05, 95% CI 0.85 to 1.30; p=0.63). The interaction was marginally significant (p=0.07). Conclusions: The modification effect of renal function on different antihypertensive timing for AIS was not observed. Further, adequately powered studies were warranted. Trial registration number: NCT03479554 .
- 12 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (9) , e214818
Associations of Accelerated Biological Aging With the Presence and Longitudinal Progression of Cerebral Small Vessel Disease
Cerebral small vessel disease (CSVD) is a major cause of dementia and stroke, typically identified by lesions such as white matter hyperintensity (WMH), lacunes, cerebral microbleeds (CMBs), enlarged perivascular spaces, and brain atrophy. Biomarker-based biological age (BA), derived from routinely measured clinical indicators and largely reflecting vascular and metabolic physiologic burden, may provide complementary information beyond chronological age. The aim of this study was to investigate the associations between BA residual and both the presence and progression of CSVD and its neuroimaging manifestations. In the population-based Polyvascular Evaluation for Cognitive Impairment and Vascular Events cohort, participants underwent brain magnetic resonance imaging (MRI) at baseline (2017-2019) and at follow-up (2022-2024). BA was estimated using 3 established methods: PhenoAge, Klemera-Doubal method, and homeostatic dysregulation. Progression of CSVD and its imaging markers, including new lacunes, new CMBs, progression of enlarged perivascular spaces in the basal ganglia (BG-EPVS), and progression of WMHs, was assessed. Associations between BA residual and progression of CSVD were analyzed using logistic or ordinal logistic regression models, as appropriate. A total of 3,050 participants were included at baseline (mean age 61.22 ± 6.67 years; 53.51% female); 2,662 completed follow-up MRI over a median of 4.7 years, and 388 were lost to follow-up. Higher BA residual, particularly KDMAge and PhenoAge residual, was associated with greater CSVD burden at baseline and follow-up. Moreover, KDMAge residual was positively associated with the progression of total CSVD burden (odds ratio [OR] = 1.18, 95% CI 1.08-1.30; p = 0.001), new lacunes (OR = 1.31, 95% CI 1.13-1.51, p < 0.001), and new CMBs (OR = 1.13, 95% CI 1.01-1.25; p = 0.028), but not with progression of BG-EPVS or WMHs at follow-up. PhenoAge residual showed results consistent with those of KDMAge residual, whereas HDAge residual showed no significant association with progression of CSVD or its imaging markers. This community-based cohort study demonstrated that BA residuals, particularly KDMAge and PhenoAge, were associated with higher odds of CSVD progression, especially with development of new lacunes and new CMBs. Biomarker-based BA residual may help identify individuals at higher risk of clinically relevant CSVD progression. Future studies with longer follow-up periods and more diverse cohorts are warranted to validate these findings.
- 12 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (9) , e214818
Associations of Accelerated Biological Aging With the Presence and Longitudinal Progression of Cerebral Small Vessel Disease
Cerebral small vessel disease (CSVD) is a major cause of dementia and stroke, typically identified by lesions such as white matter hyperintensity (WMH), lacunes, cerebral microbleeds (CMBs), enlarged perivascular spaces, and brain atrophy. Biomarker-based biological age (BA), derived from routinely measured clinical indicators and largely reflecting vascular and metabolic physiologic burden, may provide complementary information beyond chronological age. The aim of this study was to investigate the associations between BA residual and both the presence and progression of CSVD and its neuroimaging manifestations. In the population-based Polyvascular Evaluation for Cognitive Impairment and Vascular Events cohort, participants underwent brain magnetic resonance imaging (MRI) at baseline (2017-2019) and at follow-up (2022-2024). BA was estimated using 3 established methods: PhenoAge, Klemera-Doubal method, and homeostatic dysregulation. Progression of CSVD and its imaging markers, including new lacunes, new CMBs, progression of enlarged perivascular spaces in the basal ganglia (BG-EPVS), and progression of WMHs, was assessed. Associations between BA residual and progression of CSVD were analyzed using logistic or ordinal logistic regression models, as appropriate. A total of 3,050 participants were included at baseline (mean age 61.22 ± 6.67 years; 53.51% female); 2,662 completed follow-up MRI over a median of 4.7 years, and 388 were lost to follow-up. Higher BA residual, particularly KDMAge and PhenoAge residual, was associated with greater CSVD burden at baseline and follow-up. Moreover, KDMAge residual was positively associated with the progression of total CSVD burden (odds ratio [OR] = 1.18, 95% CI 1.08-1.30; p = 0.001), new lacunes (OR = 1.31, 95% CI 1.13-1.51, p < 0.001), and new CMBs (OR = 1.13, 95% CI 1.01-1.25; p = 0.028), but not with progression of BG-EPVS or WMHs at follow-up. PhenoAge residual showed results consistent with those of KDMAge residual, whereas HDAge residual showed no significant association with progression of CSVD or its imaging markers. This community-based cohort study demonstrated that BA residuals, particularly KDMAge and PhenoAge, were associated with higher odds of CSVD progression, especially with development of new lacunes and new CMBs. Biomarker-based BA residual may help identify individuals at higher risk of clinically relevant CSVD progression. Future studies with longer follow-up periods and more diverse cohorts are warranted to validate these findings.
- Open Access
- 7 May 2026
- Published by BMJ in Stroke and Vascular Neurology
Associations of albumin, globulin and albumin-to-globulin ratio with cerebral small vessel disease
Background: Albumin (ALB), globulin (GLB) and albumin-to-globulin ratio (AGR) are linked to vascular diseases, but their relationships with cerebral small vessel disease (CSVD) remain inadequately explored. This study aimed to examine the associations between these biomarkers and CSVD burden. Methods: Participants from the PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events (PRECISE) study were included. CSVD severity was assessed using total and modified CSVD burden scores derived from white matter hyperintensity (WMH), enlarged perivascular spaces in basal ganglia (BG-EPVS), lacunes and cerebral microbleeds. Logistic regression and two-sample Mendelian randomisation (MR) were employed to estimate associations and potential causal effects. Results: Among 3042 subjects (mean age 61.2 years), lower ALB, higher GLB and lower AGR were significantly associated with greater total and modified CSVD burden after adjusting for confounders. Specifically, the risk of total CSVD burden was significantly increased for the lowest ALB tertile (cOR 1.31, 95% CI 1.07 to 1.60), highest GLB tertile (cOR 1.33, 95% CI 1.09 to 1.63) and lowest AGR tertile (cOR 1.46, 95% CI 1.19 to 1.79) compared with their respective reference tertiles. Similar patterns were observed for WMH and BG-EPVS. MR analysis revealed that genetically predicted ALB was inversely associated with WMH volume (β −0.07, 95% CI −0.13 to −0.01), while genetically predicted GLB was positively associated with WMH volume (β 0.05, 95% CI 0.01 to 0.10). Conclusions: Lower ALB, higher GLB and lower AGR are associated with increased CSVD burden. Genetic evidence supports the causal roles of ALB and GLB in WMH development.
- 7 May 2026
- Published by BMJ in Stroke and Vascular Neurology
Open AccessAssociations of albumin, globulin and albumin-to-globulin ratio with cerebral small vessel disease
Background: Albumin (ALB), globulin (GLB) and albumin-to-globulin ratio (AGR) are linked to vascular diseases, but their relationships with cerebral small vessel disease (CSVD) remain inadequately explored. This study aimed to examine the associations between these biomarkers and CSVD burden. Methods: Participants from the PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events (PRECISE) study were included. CSVD severity was assessed using total and modified CSVD burden scores derived from white matter hyperintensity (WMH), enlarged perivascular spaces in basal ganglia (BG-EPVS), lacunes and cerebral microbleeds. Logistic regression and two-sample Mendelian randomisation (MR) were employed to estimate associations and potential causal effects. Results: Among 3042 subjects (mean age 61.2 years), lower ALB, higher GLB and lower AGR were significantly associated with greater total and modified CSVD burden after adjusting for confounders. Specifically, the risk of total CSVD burden was significantly increased for the lowest ALB tertile (cOR 1.31, 95% CI 1.07 to 1.60), highest GLB tertile (cOR 1.33, 95% CI 1.09 to 1.63) and lowest AGR tertile (cOR 1.46, 95% CI 1.19 to 1.79) compared with their respective reference tertiles. Similar patterns were observed for WMH and BG-EPVS. MR analysis revealed that genetically predicted ALB was inversely associated with WMH volume (β −0.07, 95% CI −0.13 to −0.01), while genetically predicted GLB was positively associated with WMH volume (β 0.05, 95% CI 0.01 to 0.10). Conclusions: Lower ALB, higher GLB and lower AGR are associated with increased CSVD burden. Genetic evidence supports the causal roles of ALB and GLB in WMH development.
- 22 January 2026
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (8) , 1108-1118
Decompressive hemicraniectomy for large hemispheric infarction after endovascular therapy
Background: Although endovascular therapy (EVT) improves functional outcomes in acute ischemic stroke patients, some with large hemispheric infarction (LHI) post-EVT may still require decompressive hemicraniectomy (DHC). This study aimed to explore whether DHC benefits all patients with post-EVT LHI and to identify which patients are more likely to benefit from DHC. Methods: This pooled analysis of the RESCUE-RE study and the ANGEL-ASPECT trial enrolled patients with LHI and severe neurological deficits after EVT. According to the treatment received, patients were categorized into DHC and conservative therapy groups. The primary outcome was 90-day mortality. Propensity score matching (PSM) analysis was used to control for differences between groups. Results: In total, 136 of 2036 EVT-treated patients (6.7%) in the RESCUE-RE study and 59 of 230 (25.6%) in the ANGEL-ASPECT trial met inclusion criteria. Among the 195 patients included, 50 (25.6%) underwent DHC (41 after PSM), while 145 (74.4%) received conservative therapy (41 after PSM). Patients undergoing DHC after EVT had significantly lower 90-day mortality rates compared with those receiving conservative therapy (odds ratio (OR) = 0.26; 95% confidence interval (CI), 0.10–0.66; p = 0.005), but no significant improvement was observed in 90-day modified Rankin Scale (mRS) distribution (common OR = 0.47; 95% CI = 0.21–1.05; p = 0.06). Patients within an overlapping range of post-EVT midline shift (approximately 10–17 mm) or infarct volume (approximately 250–330 mL), where both 90-day mortality and ordinal mRS distribution models favored DHC, appeared more likely to derive a comprehensive clinical benefit. Baseline infarct-core volume was not associated with the treatment effect of DHC. Conclusion: In patients with LHI after EVT, DHC was associated with reduced mortality when performed in accordance with current guidelines. Moreover, patients within a higher, but not the most extreme, range of injury severity after EVT might be more likely to benefit from DHC.
- 22 January 2026
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (8) , 1108-1118
Decompressive hemicraniectomy for large hemispheric infarction after endovascular therapy
Background: Although endovascular therapy (EVT) improves functional outcomes in acute ischemic stroke patients, some with large hemispheric infarction (LHI) post-EVT may still require decompressive hemicraniectomy (DHC). This study aimed to explore whether DHC benefits all patients with post-EVT LHI and to identify which patients are more likely to benefit from DHC. Methods: This pooled analysis of the RESCUE-RE study and the ANGEL-ASPECT trial enrolled patients with LHI and severe neurological deficits after EVT. According to the treatment received, patients were categorized into DHC and conservative therapy groups. The primary outcome was 90-day mortality. Propensity score matching (PSM) analysis was used to control for differences between groups. Results: In total, 136 of 2036 EVT-treated patients (6.7%) in the RESCUE-RE study and 59 of 230 (25.6%) in the ANGEL-ASPECT trial met inclusion criteria. Among the 195 patients included, 50 (25.6%) underwent DHC (41 after PSM), while 145 (74.4%) received conservative therapy (41 after PSM). Patients undergoing DHC after EVT had significantly lower 90-day mortality rates compared with those receiving conservative therapy (odds ratio (OR) = 0.26; 95% confidence interval (CI), 0.10–0.66; p = 0.005), but no significant improvement was observed in 90-day modified Rankin Scale (mRS) distribution (common OR = 0.47; 95% CI = 0.21–1.05; p = 0.06). Patients within an overlapping range of post-EVT midline shift (approximately 10–17 mm) or infarct volume (approximately 250–330 mL), where both 90-day mortality and ordinal mRS distribution models favored DHC, appeared more likely to derive a comprehensive clinical benefit. Baseline infarct-core volume was not associated with the treatment effect of DHC. Conclusion: In patients with LHI after EVT, DHC was associated with reduced mortality when performed in accordance with current guidelines. Moreover, patients within a higher, but not the most extreme, range of injury severity after EVT might be more likely to benefit from DHC.
- 29 November 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (5) , 676-687
Significance of occlusion site on outcomes in stroke patients with large infarction undergoing endovascular therapy: A prespecified subgroup analysis of the ANGEL-ASPECT trial
Background: Randomized studies have demonstrated the efficacy of endovascular therapy (EVT) for acute large vessel occlusion with large infarction. However, the impact of the occlusion site on EVT outcomes remains underexplored. Methods: We conducted this prespecified subgroup analysis of the Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients with a Large Infarct Core (ANGEL-ASPECT) trial. Participants were enrolled within 24 h of symptom onset and had an Alberta Stroke Program Early Computed Tomography Score of 3 to 5 or an infarct core volume of 70–100 mL and were randomly assigned to undergo EVT or standard medical management (MM). All 455 patients were included and categorized into 2 subgroups by whether there was an internal carotid artery occlusion (ICAO) or middle cerebral artery occlusion (MCAO). The primary outcome was functional outcome (modified Rankin Scale) at 90 days. We further assessed the association between onset-to-puncture time (OPT) and outcome in both groups using ordinal logistic regression and tested for an interaction between occlusion site and the effect of EVT. Results: A total of 164 patients (36.0%) had ICAO, while 291 patients (64.0%) had MCAO. The baseline characteristics of patients treated with EVT and MM were comparable in either the ICAO or MCAO groups. EVT benefit was observed in both groups without significant heterogeneity (p for interaction = 0.891). A significant statistic interaction between occlusion site and treatment on any intracranial hemorrhage (ICH) within 48 h was observed (p for interaction = 0.002), with ICAO significantly increasing the risk of ICH compared to MCAO in patients undergoing EVT (ICAO: common OR, 6.34; 95% CI, 2.84–14.16; MCAO: common OR, 2.19; 95% CI, 1.56–3.09). However, the risk of symptomatic ICH was not increased significantly in both groups. For patients with ICAO, when OPT exceeds about 10 h and 10 min, the benefit of EVT compared to MM is not significant. Conclusions: Although both ICAO and MCAO patients with large infarction could benefit from EVT, EVT increased the risk of any ICH in ICAO patients without increasing the risk of sICH. Longer OPT was associated with poorer EVT efficacy in patients with ICAO. Data access statement: The data supporting the findings of this study are available from the corresponding author upon reasonable request. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04551664.
- 29 November 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (5) , 676-687
Significance of occlusion site on outcomes in stroke patients with large infarction undergoing endovascular therapy: A prespecified subgroup analysis of the ANGEL-ASPECT trial
Background: Randomized studies have demonstrated the efficacy of endovascular therapy (EVT) for acute large vessel occlusion with large infarction. However, the impact of the occlusion site on EVT outcomes remains underexplored. Methods: We conducted this prespecified subgroup analysis of the Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients with a Large Infarct Core (ANGEL-ASPECT) trial. Participants were enrolled within 24 h of symptom onset and had an Alberta Stroke Program Early Computed Tomography Score of 3 to 5 or an infarct core volume of 70–100 mL and were randomly assigned to undergo EVT or standard medical management (MM). All 455 patients were included and categorized into 2 subgroups by whether there was an internal carotid artery occlusion (ICAO) or middle cerebral artery occlusion (MCAO). The primary outcome was functional outcome (modified Rankin Scale) at 90 days. We further assessed the association between onset-to-puncture time (OPT) and outcome in both groups using ordinal logistic regression and tested for an interaction between occlusion site and the effect of EVT. Results: A total of 164 patients (36.0%) had ICAO, while 291 patients (64.0%) had MCAO. The baseline characteristics of patients treated with EVT and MM were comparable in either the ICAO or MCAO groups. EVT benefit was observed in both groups without significant heterogeneity (p for interaction = 0.891). A significant statistic interaction between occlusion site and treatment on any intracranial hemorrhage (ICH) within 48 h was observed (p for interaction = 0.002), with ICAO significantly increasing the risk of ICH compared to MCAO in patients undergoing EVT (ICAO: common OR, 6.34; 95% CI, 2.84–14.16; MCAO: common OR, 2.19; 95% CI, 1.56–3.09). However, the risk of symptomatic ICH was not increased significantly in both groups. For patients with ICAO, when OPT exceeds about 10 h and 10 min, the benefit of EVT compared to MM is not significant. Conclusions: Although both ICAO and MCAO patients with large infarction could benefit from EVT, EVT increased the risk of any ICH in ICAO patients without increasing the risk of sICH. Longer OPT was associated with poorer EVT efficacy in patients with ICAO. Data access statement: The data supporting the findings of this study are available from the corresponding author upon reasonable request. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04551664.
- 18 November 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (7) , 999-1008
Cognitive impairment in acute ischemic stroke patients with early versus delayed antihypertensive treatment: A prespecified analysis of CATIS-2 trial
Background: The optimal timing for initiating antihypertensive therapy after acute ischemic stroke (AIS), particularly regarding cognitive outcomes, remains uncertain. This study investigated the association between treatment timing and 3-month cognitive function. Methods: This prespecified analysis of the China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2) included patients completing 3-month Montreal Cognitive Assessment (MoCA). Participants were randomized to early (immediate) or delayed (day 8) antihypertensive treatment, with MoCA score as primary outcome. Results: A total of 1682 patients completed the cognitive assessment; 823 received early antihypertensive treatment and 859 received delayed treatment. Baseline characteristics were comparable between the two groups. The median MoCA score was 23 in both groups (β, -0.06; 95% CI, -0.16 to 0.03; P = .19). In addition, the proportion of individuals with MoCA scores < 25 was similar between the two groups (62% vs 59%; OR, 1.15; 95% CI, 0.95 to 1.40; P = 0.16). Exploratory subgroup analyses suggested a potential interaction by prior antihypertensive use, whereby early antihypertensive treatment was associated with worse cognitive outcomes in patients with prior antihypertensive use (OR, 1.34; 95% CI, 1.01–1.77; p = 0.03; P for interaction = 0.04). Conclusions: Early antihypertensive initiation did not improve 3-month cognitive outcomes in AIS patients, highlighting the importance of individualized therapy, especially for high-risk PSCI subgroups.
- 18 November 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (7) , 999-1008
Cognitive impairment in acute ischemic stroke patients with early versus delayed antihypertensive treatment: A prespecified analysis of CATIS-2 trial
Background: The optimal timing for initiating antihypertensive therapy after acute ischemic stroke (AIS), particularly regarding cognitive outcomes, remains uncertain. This study investigated the association between treatment timing and 3-month cognitive function. Methods: This prespecified analysis of the China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2) included patients completing 3-month Montreal Cognitive Assessment (MoCA). Participants were randomized to early (immediate) or delayed (day 8) antihypertensive treatment, with MoCA score as primary outcome. Results: A total of 1682 patients completed the cognitive assessment; 823 received early antihypertensive treatment and 859 received delayed treatment. Baseline characteristics were comparable between the two groups. The median MoCA score was 23 in both groups (β, -0.06; 95% CI, -0.16 to 0.03; P = .19). In addition, the proportion of individuals with MoCA scores < 25 was similar between the two groups (62% vs 59%; OR, 1.15; 95% CI, 0.95 to 1.40; P = 0.16). Exploratory subgroup analyses suggested a potential interaction by prior antihypertensive use, whereby early antihypertensive treatment was associated with worse cognitive outcomes in patients with prior antihypertensive use (OR, 1.34; 95% CI, 1.01–1.77; p = 0.03; P for interaction = 0.04). Conclusions: Early antihypertensive initiation did not improve 3-month cognitive outcomes in AIS patients, highlighting the importance of individualized therapy, especially for high-risk PSCI subgroups.
- 29 September 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (4) , 539-551
Associations between endothelial inflammatory markers and cerebral small vessel disease in a community-based population
Background: Endothelial inflammation is involved in cerebral small vessel disease (CSVD) pathogenesis. Vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) are biomarkers of endothelial inflammation. Aims: This study investigated the association of VCAM-1 and ICAM-1 with the presence of CSVD and CSVD burden. Methods: This cross-sectional study included community residents from the Polyvascular Evaluation for Cognitive Impairment and Vascular Events (PRECISE) study. Fasting venous blood was drawn to assay VCAM-1 and ICAM-1. Cognition was assessed by the Montreal Cognitive Assessment (MoCA). Cognitive impairment was defined as MoCA scores < 26. White matter hyperintensity, lacunes, cerebral microbleeds, and enlarged perivascular spaces were evaluated in a 3.0T MRI scanner. CSVD burden was rated according to the criteria of Wardlaw’s (score 0–4) and Rothwell’s (score 0–6), and classified into four grades. Presence of CSVD was defined as CSVD burden score ⩾ 1. Results: This study included 2596 participants with a mean age of 61.2 ± 6.7 years and 50.9% of males. Elevated VCAM-1 was associated with increased odds of presence of CSVD (Rothwell: odds ratio (OR) = 1.16, 95% confidence interval (CI): 1.06–1.26, P = 0.001), higher CSVD burden (Wardlaw: common OR (cOR) = 1.11, 95% CI: 1.02–1.21, P = 0.02; Rothwell: cOR = 1.16, 95% CI: 1.07–1.25, P < 0.001), and presence of cognition-impaired CSVD (Rothwell: OR = 1.15, 95% CI: 1.05–1.25, P = 0.003). VCAM-1 improved net reclassification index and integrated discrimination improvement for the presence of CSVD (Rothwell) and cognition-impaired CSVD (Rothwell). However, ICAM-1 was not associated with CSVD and did not improve prediction of CSVD. Conclusion: Endothelial inflammation, especially VCAM-1, was associated with the presence of CSVD and higher CSVD burden.
- 29 September 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (4) , 539-551
Associations between endothelial inflammatory markers and cerebral small vessel disease in a community-based population
Background: Endothelial inflammation is involved in cerebral small vessel disease (CSVD) pathogenesis. Vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) are biomarkers of endothelial inflammation. Aims: This study investigated the association of VCAM-1 and ICAM-1 with the presence of CSVD and CSVD burden. Methods: This cross-sectional study included community residents from the Polyvascular Evaluation for Cognitive Impairment and Vascular Events (PRECISE) study. Fasting venous blood was drawn to assay VCAM-1 and ICAM-1. Cognition was assessed by the Montreal Cognitive Assessment (MoCA). Cognitive impairment was defined as MoCA scores < 26. White matter hyperintensity, lacunes, cerebral microbleeds, and enlarged perivascular spaces were evaluated in a 3.0T MRI scanner. CSVD burden was rated according to the criteria of Wardlaw’s (score 0–4) and Rothwell’s (score 0–6), and classified into four grades. Presence of CSVD was defined as CSVD burden score ⩾ 1. Results: This study included 2596 participants with a mean age of 61.2 ± 6.7 years and 50.9% of males. Elevated VCAM-1 was associated with increased odds of presence of CSVD (Rothwell: odds ratio (OR) = 1.16, 95% confidence interval (CI): 1.06–1.26, P = 0.001), higher CSVD burden (Wardlaw: common OR (cOR) = 1.11, 95% CI: 1.02–1.21, P = 0.02; Rothwell: cOR = 1.16, 95% CI: 1.07–1.25, P < 0.001), and presence of cognition-impaired CSVD (Rothwell: OR = 1.15, 95% CI: 1.05–1.25, P = 0.003). VCAM-1 improved net reclassification index and integrated discrimination improvement for the presence of CSVD (Rothwell) and cognition-impaired CSVD (Rothwell). However, ICAM-1 was not associated with CSVD and did not improve prediction of CSVD. Conclusion: Endothelial inflammation, especially VCAM-1, was associated with the presence of CSVD and higher CSVD burden.